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Clear cell ovarian cancer (OCCA) is an uncommon subtype of epithe-
lial ovarian cancer accounting for less than 10% of clinical cases in most
reported cohorts (Fujiwara et al., 2016). Whereas the precursor cell of
the more common high grade serous ovarian (HGS) cancer has been
hypothesised to be secretory epithelium of the distal fallopian tube
the precursor of clear cell ovarian cancer is less clear. The recent associ-
ation of clear cell histology (Wentzensen et al., 2016) with previous
areas of endometriosis has pointed towards an entirely different cell
of origin and indeed molecular characterisation has conﬁrmed this fun-
damental disparity between HGS and OCCA.
The poor response rates to cytotoxic chemotherapy in the setting of
advanced disease in the order of 10–30% (Magazzino et al., 2011) and
molecular characteristics of these tumours (Anon, 2013) have
prompted investigators to propose treatment of OCCA with sunitinib
maleate, a multi-active RTK inhibitor with selectivity for PDGFRa,
VEGFR and c-MET, as a potential therapeutic option in this disease
(Friedlander et al., 2016). To our knowledge only one previously pub-
lished report demonstrating activity of sunitinib in clear cell ovarian
cancer exists (Anglesio et al., 2011). This report illustrates a response
to sunitinib in a patient with parenchymal hepatic deposits and chemo-
therapy refractory OCCA.⁎ Corresponding author at: Dept. ofMedical Oncology, Hammersmith Hospital, Du Cane
Road, W12 0HS London, United Kingdom.
E-mail address: costi@doctors.org.uk (C. Alifrangis).
http://dx.doi.org/10.1016/j.gore.2016.11.001
2352-5789/© 2016 The Authors. Published by Elsevier Inc. This is an open access article under1.1. Case description
A 59 year old patient was discussed at the gynaecologic oncology
multi-disciplinary meeting having presented with abdominal disten-
sionwith radiological features of an ovarianmalignancy. A CT scan dem-
onstrated a complex 16 cm × 13 cmmass arising in the pelvis from the
right ovary. Her baseline serum tumour marker ca125 was 34 U/ml She
had no medical history of note and was previously ﬁt and well. Her
ECOG performance status was 1. There was no family history of
malignancy.
A primary debulking procedure was carried out including Total ab-
dominal hysterectomy, Bilateral salpingo-oophorectomy, omentectomy
and peritoneal stripping, to no residual macroscopic disease. The histo-
pathologic assessment of the tumour revealed a FIGO Stage IIIA2 clear
cell ovarian carcinoma by virtue of omental involvement. There was
no background of co-existing endometriosis noted. A course of adjuvant
chemotherapy with carboplatin and paclitaxel was prescribed but fol-
lowing theﬁrst cycle of platinumdoublet therapy the patient developed
a signiﬁcantmyocardial infarction, and a worsening of her performance
status to ECOG P2. Adjuvant treatment was then withheld and the pa-
tient was placed on outpatient surveillance.
15months later she reported increasing lethargy and abdominal dis-
tension. A CT scan performed at this time demonstrated a recurrence of
her disease with multiple parenchymal liver deposits, the largest mea-
suring 3 cm in diameter, peritoneal deposits and lymphadenopathy at
the porta hepatis. A modiﬁed retreatment regiment of platinum con-
taining chemotherapywith nitrate cover was utilised. The patient toler-
ated this well with no further cardiac events. Unfortunately after
2 cycles a re-staging CT demonstrated progression in the size of the
nodal disease and hepatic deposits - the largest lesion measuring
5.5 cm in diameter.
At this point sunitinib was obtained and the patient agreed to self-
fund its off license use in the setting of chemotherapy refractory disease.
Sunitinib was commenced at a dose of 50 mg od in the intermittent dos-
ing schedule as per the Motzer et al. pivotal study in renal cell carcinoma
(Motzer et al., 2007). After four weeks of treatment themain toxicity was
grade I-II fatigue. Unfortunately the patientwas then admittedwith rectal
bleeding and the sunitinib withheld. Colonoscopy and Oesophogastric
duodenoscopy failed to identify a bleeding focus, and the bleeding settled
with conservativemanagement. However given the possible contribution
of sunitinib, a decision was made that it should be discontinued. Duringthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. A) Pre treatment CT CAP demonstrating hepatic deposit measuring 55 mm. B) Following 4 weeks of sunitinib this now measures 25 mm.
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ed a reduction in the size and volume of the multiple hepatic parenchy-
mal metastatic deposits compared to the pre treatment imaging. The
largest of these reduced in size from 55–25 mmwith a concomitant im-
provement in symptoms of right upper quadrant discomfort. A represen-
tative image is shown in Fig. 1. The patient has now been off treatment
and on follow up for 2 months. She has unfortunately since declined in
her performance status and no further treatment is planned. She is cur-
rently being supported by the community palliative care team.
2. Discussion
To our knowledge this Is only the third report in the literature dem-
onstrating that sunitinib monotherapy can provoke a response in che-
motherapy refractory clear cell ovarian cancer. Pre-clinical data has
demonstrated distinct molecular characteristics of these tumours,
more similar in their somatic mutation burden to clear cell renal carci-
noma than the more common high grade serous subtype. Speciﬁcally
in comparison to more common types of EOC, somatic mutations in
p53 are usually absent, with high levels of activation of PI3Kinase path-
way signalling, either through inactivation of PTEN or throughmissense
variants causing activation in PIK3CA. Other interesting mutations
enriched for in OCCA include inactivation of the chromatin remodelling
gene ARID1A which is a member of the SWI/SNF complex, notably also
recurrently inactivated in clear cell renal carcinoma (Friedlander et al.,
2016; Jones et al., 2010; Rauh-Hain and Penson, 2008; Anon, 2013).
There is a clear rationale to target angiogenesis and multiple RTKs
given the overexpression of the IL6-HIF-STAT3 pathway in these can-
cers compared to high grade serous ovarian cancer (Anglesio et al.,
2011).
Previous phase II studies of sunitinib in ovarian carcinomahave been
undertaken in unselected ovarian cancer histological groups. A phase II
study in relapsed epithelial ovarian/fallopian/Primary peritoneal cancer
(Biagi et al., 2011) recruited 30 patients. Three patients had a measur-
able response - all in the platinum sensitive population and all on inter-
mittent rather than continuous lower dose (37.5 mg) dosing regimens.
The AGO study group have since evaluated the 50 mg intermittent reg-
imen compared to continuous dosing of 37mg in a phase 2 study in the
platinum resistant setting. 73 patients recruited into the study
(Baumann et al., 2012) and in the non-continuous dosing group there
were 6 responses compared to 2 responses in the continuous group. In-
terestingly in renal cell carcinoma the intermittent sunitinib dosing reg-
imen has a conﬁrmed efﬁcacy signal over the continuous regimen
(Motzer et al., 2012). One other published study has speciﬁcally exam-
ined the role of sunitinib in OCCA where the above molecular ﬁndings
perhaps provide more of a biological justiﬁcation than in other groups
of EOC. In the study reported by Bowtell and colleagues two partial re-
sponses to sunitinib were reported in chemotherapy refractory OCCA,both in patients with large volume nodal or visceral disease outside
the pelvis. A further study reported the short term response of a single
patient to sunitinib in the ﬁfth line setting (Rauh-Hain and Penson,
2008). The eagerly awaited GOG254 sunitinib phase II study, although
not published has been presented in abstract form. This demonstrated
an overall response rate of 7% in OCCA. Given the pre-clinical data and
encouraging reports of responses in chemotherapy refractory patients
such as that presented here this is clearly disappointing. One could spec-
ulate that a biomarker for a sensitive subgroup exists, but this has not
yet been elucidated. It may be that alternative or combination strategies
are necessary to improve on the response rates in the GOG254 study
and recent data has however demonstrated other avenues that may
be clinically relevant to extend this efﬁcacy spectrum of small molecule
inhibitors in this disease. The epistatic relationship between the SWI/
SNF complex and PIK3CA mutations in OCCA have been shown con-
verge on and drive IL-6 signalling and a panPI3K inhibitor has shown ef-
ﬁcacy in pre-clinical models of OCCA (Chandler et al., 2015).
Furthermore a recent paper demonstrated a novel synthetic lethal rela-
tionship between inhibition of the EZH2 methyltransferase in ARID1A
mutant tumours (Bitler et al., 2015). A strategy to target IL-6 using
monoclonal antibodies such as the approved therapy for rheumatoid ar-
thritis Tocilizumab has just entered early stage trials in ovarian cancer
(Dijkgraaf et al., 2015) and one could foresee its particular applicability
in OCCA given the data presented above.
In terms of practical use of this agent the report presented here also
highlights the speciﬁc toxicities that treating oncologists should be
aware of, speciﬁcally thewell reported complication of gastro-intestinal
bleeding events. In our patient this necessitated stopping the drug de-
spite an impressive response in the burden of hepatic parenchymal me-
tastases. It must be noted that this is an unusual toxicity with the most
common adverse events seen being fatigue, diarrhea, nausea and dia-
stolic hypertension (Motzer et al., 2012). It is useful to note that in the
pivotal studies in renal cancer the discontinuation rate due to AE's is
around 15% with approximately 40% of patients requiring dose adjust-
ment to manage these toxicities.
In summary sunitinib used off license in clear cell histology has demon-
stratedmeaningful and encouraging responses in patients with otherwise
chemotherapy refractory disease. This has not however been replicated
widely in a recently reported phase II study. In the absence of validated
biomarkers to identify responders to sunitinibnovel strategies are urgently
needed. Early data exists for alternative small molecule inhibitors which
may give hope in this population of chemo-refractory patients.Consent and conﬂict of interest statements
Informed consent for publication of this casewas obtained inwriting
from the patient prior to publication.
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